Current Report Filing (8-k)
October 29 2019 - 1:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): October 29, 2019
Generex
biotechnology corpORATION
(Exact of registrant as specified in
its charter)
DELAWARE
|
000-29169
|
98-0178636
|
State or other jurisdiction of incorporation
|
Commission File Number
|
IRS Employer Identification №.
|
10102 USA Today Way, Miramar, Florida
33025
(Address of principal executive
offices) (Zip Code)
(416) 364-2551
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter) ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13 (a) of the Exchange Act. ¨
|
Item 3.03.
|
Material Modification to Rights of Security Holders.
|
On October 29, 2019, Generex Biotechnology Corporation
(“Generex”) announced an extension of the payment date for the common stock dividend on its shares of common
stock, par value $.001 per share, at a ratio of 1 for 1, previously declared by the Board of Directors. The pay
date for the 1:1 dividend has been extended 30 days to Thursday December 12, 2019. The
record date remains August 30th, 2019.
On October 29, 2019, Generex issued a press
release related to the dividend payment extension, a copy of which is furnished herewith as Exhibit 99.1, announcing the extension
of the payment date for the common stock dividend.
The press release attached hereto as Exhibit
99.1, is being furnished pursuant to this Item 8.01 and shall not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange
Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to Item 8.01
of this Current Report on Form 8-K.
The information contained in the press release
is summary information that is intended to be considered in the context of Generex’s filings with the SEC and other public
announcements that Generex makes, by press release or otherwise, from time to time. Generex undertakes no duty or obligation to
publicly update or revise the information contained in this report, although it may do so from time to time as its management believes
is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases
or through other public disclosure.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: Tuesday, October 29, 2019
Generex Biotechnology Corp.
/s/Joe Moscato
By: Joe Moscato, CEO, President